Pharming extends Ruconest distribution agreement with Cytobioteck
9 February 2016 | By Victoria White
Under the extended agreement, Cytobioteck will also exclusively distribute Ruconest in Argentina, Costa Rica, the Dominican Republic and Panama...
List view / Grid view
9 February 2016 | By Victoria White
Under the extended agreement, Cytobioteck will also exclusively distribute Ruconest in Argentina, Costa Rica, the Dominican Republic and Panama...
6 January 2016 | By Victoria White
Pharming has completed patient enrolment in the Phase 2 clinical study of Ruconest (recombinant C1 esterase Inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...